Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Glaxo and ICI rapped over prices

Gail Counsell,Business Correspondent
Wednesday 03 February 1993 19:02 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

GLAXO and ICI's American subsidiaries have been criticised in a US Senate report for increasing drug prices faster than inflation despite promises to the contrary.

In 1992 the US drug inflation rate was 6.4 per cent, four times the general inflation rate of 1.5 per cent, the report said.

It claimed that eight of the top 31 US drug manufacturers - Glaxo, ICI-Stuart, Merck, Pfizer, Marion Merrell-Dow, Hoffman La Roche, Dupont-Merck and Sterling Winthrop - increased their prices by more than three times the inflation rate.

Moreover, 19 of the top 31 increased out-patient prices at double the inflation rate, it said.

But many of the companies challenged the basis on which the study's calculations were made. A spokesman for Glaxo said it had ignored total sales and looked only at individual drugs.

The overall increase in the price of all Glaxo product lines in the financial year to the end of June 1992 was 1.8 per cent, well below the general rate of inflation for the same period, which had been around 3 per cent.

Pharmaceutical company shares have been hit in recent months because of fears about greater control of drug prices - about dollars 67bn, or 10 per cent of the total 1990 US health care bill was spent on drugs.

View from City Road, page 27

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in